

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1644
		Examiner Name	Francois P Vandervegt
		Attorney Docket Number	IMG 101
Sheet	1	of	3

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/PVI/		5,726,288		Call, et al.	03-10-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ²	Number ⁴	Kind Code ⁵ (if known)				

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1644
		Examiner Name	Francois P Vandervegt
		Attorney Docket Number	IMG 101
Sheet	2	of	3

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
IPV/		CONDON, et al., "DNA-based immunization by in vivo transfection of dendritic cells", <i>Nat. Med.</i> , 2(10):1122-8 (1996).	
		CONRY, et al., "Polynucleotide-mediated immunization therapy of cancer", <i>Semin. Oncol.</i> , 23(1):135-47 (1996).	
		GESSLER, et al., "Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping", <i>Nature</i> , 343(6260):774-8 (1990).	
		GONG, et al., "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells", <i>Nat. Med.</i> , 3(5):558-61 (1997).	
		GRAHAM, et al. "Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells", <i>Int. J. Cancer</i> , 65(5):664-70 (1996).	
		INOUE, et al., "Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels", <i>Blood</i> , 88(6):2267-78 (1996).	
		KAST, et al., "Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes", <i>Cell</i> , 59(4):603-14 (1989).	
		KAWAKAMI, et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 91(14):6458-62 (1994).	
		MENSSEN, et al., "Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias", <i>Leukemia</i> , 9(6):1060-7 (1995).	
		MENSSEN, et al., "Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia", <i>Int. J. Cancer</i> , 70(5):518-23 (1997).	
V		MURPHY, et al., "Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen", <i>Prostate</i> , 29(6):371-80 (1996).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/625,963	
			Filing Date	July 26, 2000	
			First Named Inventor	Hans Josef Stauss	
			Group Art Unit	1644	
			Examiner Name	Francois P Vandervegt	
			Attorney Docket Number	IMG 101	
Sheet	3	of	3		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
IPV/ ↓		OGAWA, et al., "Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay", <i>Bone Marrow Transplant</i> , 21(5):525-7 (1998).	
		SHIMAMOTO, et al., "The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia", <i>Blood</i> , 86(8):3173-80 (1995).	
		SILBERSTEIN, et al., "Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 94(15):8132-7 (1997).	
		TJOA, et al., "Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides", <i>Prostate</i> , 32(4):272-8 (1997).	
		TOURDOT, et al., "Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination", <i>J. Immunol.</i> , 159(5):2391-8 (1997).	
		VIEL, et al., "Molecular mechanisms possibly affecting WT1 function in human ovarian tumors", <i>Int. J. Cancer</i> , 57(4):515-21 (1994).	
		ZHAI, et al., "Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy", <i>J. Immunol.</i> , 158(2):700-10 (1996).	
↓		ZON, et al. "The major human erythroid DNA-binding protein (GF-1): primary sequence and localization of the gene to the X chromosome", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 87(2):668-72 (1990).	

Examiner's Signature	/F. Pierre VanderVegt/	Date Considered	03/19/2007
----------------------	------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.